C. Rohlff

发表

Annotation of the Human Genome by High-Throughput Sequence Analysis of Naturally Occurring Proteins

C. Freeman, Clive Brown, M. Schenker, 2004 .

Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1.

R. Glazer, C. Rohlff, 1998, International journal of oncology.

Reversal of resistance to adriamycin by 8-chloro-cyclic AMP in adriamycin-resistant HL-60 leukemia cells is associated with reduction of type I cyclic AMP-dependent protein kinase and cyclic AMP response element-binding protein DNA-binding activities.

R. Glazer, Y. Cho‐Chung, C. Rohlff, 1993, Molecular pharmacology.

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

W. Hiddemann, J. Terrett, C. Rohlff, 2017, Oncotarget.

New approaches towards integrated proteomic databases and depositories

C. Rohlff, Christian Rohlff, 2004, Expert review of proteomics.

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.

L. Cascione, D. Rossi, A. Stathis, 2020, Haematologica.

Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1

E. Kyle, M. Blagosklonny, J. Trepel, 1998, The Prostate.

A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.

T. Morris, S. Watson, A. Jackman, 1999, Cancer research.

1374 Characterization and validation of a humanized lead antibody against OX003, a novel immuno-oncology target

C. Rohlff, C. Peddaboina, Arnima Bisht, 2022, Regular and Young Investigator Award Abstracts.

Proteomic approaches to central nervous system disorders.

C. Southan, C. Rohlff, 2002, Current opinion in molecular therapeutics.

Regulation of multidrug resistance through the cAMP and EGF signalling pathways.

R. Glazer, C. Rohlff, 1995, Cellular signalling.

The Regulatory Subunit of cAMP-Dependent Protein Kinase as a Target for Cancer Diagnosis and Therapy

A. Cereseto, Y. Cho‐Chung, A. Budillon, 1993 .

8-chloroadenosine 3',5'-monophosphate as a novel modulator of multidrug-resistance.

R. Glazer, K. Cowan, H. Yokozaki, 1993, International journal of oncology.

8-Cl-cAMP induces truncation and down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells.

Y. Cho‐Chung, C. Rohlff, T. Clair, 1993, The Journal of biological chemistry.

Modulation of Transcription Factor Sp1 by cAMP-dependent Protein Kinase*

R. Glazer, C. Rohlff, F. Borellini, 1997, The Journal of Biological Chemistry.

Transcriptional regulation of multidrug resistance in breast cancer

R. Glazer, C. Rohlff, 2004, Breast Cancer Research and Treatment.

Retroviral vector-mediated overexpression of the RII beta subunit of the cAMP-dependent protein kinase induces differentiation in human leukemia cells and reverts the transformed phenotype of mouse fibroblasts.

G. Merlo, G. Tortora, H. Yokozaki, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

A role for mitogen kinase kinase 3 in pulmonary inflammation validated from a proteomic approach.

B. O'connor, M. Marber, C. Page, 2014, Pulmonary pharmacology & therapeutics.

Post-translational modification of proteins and the discovery of new medicine.

R. Parekh, C. Rohlff, R B Parekh, 1997, Current opinion in biotechnology.

Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

R. Pieters, K. Sikora, W. Siegert, 1991, Journal of Cancer Research and Clinical Oncology.

Proteomics in neuropsychiatric disorders.

C. Rohlff, 2001, The international journal of neuropsychopharmacology.

Proteomics in molecular medicine: Applications in central nervous systems disorders

C. Rohlff, 2000, Electrophoresis.

Modern proteomic strategies in the study of complex neuropsychiatric disorders

Katherine Hollis, C. Rohlff, 2003, Biological Psychiatry.

MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors

J. Arribas, M. Binaschi, J. Terrett, 2019, Molecular Cancer Therapeutics.

Hyaluronidase gene profiling and role of HYAL‐1 overexpression in an orthotopic model of prostate cancer

G. Box, S. Eccles, J. Terrett, 2002, International journal of cancer.

Proteomic approaches in drug discovery and development.

Stephen A. Williams, P. Snyder, H. Soares, 2004, International review of neurobiology.